Overexpression of lipid metabolic genes regulating the activity of ACLY, ACC, and FASN has been consistently correlated with the increased neoplastic cell proliferation, induction of pro-oncogenic signaling, tumor growth, worse clinicopathological features such as tumor stage, lymph-node positivity, migratory-invasive and metastatic potential, resistance to chemotherapeutics-induced apoptotic cell-death, shorter time to recurrence, reduced survival, and overall poor clinical outcome [61,62]. This evidence concerns the gene ACLY and neoplasm.